{
  "docId": "019de071-f579-76ad-bea5-b34da2c83a75",
  "docSlug": "563487226462eb4ab63630eb9b74a5cf",
  "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 42 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 42,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "appendix_methodology",
  "function": "present_framework",
  "density": "overcrowded",
  "nDataPoints": 1,
  "notes": "The slide uses a standard clinical trial flow diagram (randomization process).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-f579-76ad-bea5-b34da2c83a75/10",
  "deckHref": "/decks/019de071-f579-76ad-bea5-b34da2c83a75",
  "deckJsonHref": "/decks/019de071-f579-76ad-bea5-b34da2c83a75.json",
  "deckAnchorHref": "/decks/019de071-f579-76ad-bea5-b34da2c83a75#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.92,
        "x": 0.04,
        "y": 0.25
      },
      "kind": "diagram",
      "text": "Randomization flow from eligibility to treatment arms",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d5f9f54e-733f-4f2d-abc9-2fe2f969a5ce",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.42,
        "x": 0.54,
        "y": 0.56
      },
      "kind": "list",
      "text": "Primary and secondary objectives",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "697f4521-a8bc-4a50-bb00-3108af74db6c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.38,
        "x": 0.04,
        "y": 0.58
      },
      "kind": "list",
      "text": "Stratification factors",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c13d1fbe-83e9-4cce-9a77-8ada7729b8e6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.38,
        "x": 0.04,
        "y": 0.25
      },
      "kind": "list",
      "text": "Key eligibility criteria",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c385f098-133f-4444-be61-a51930d91a0f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.92,
        "x": 0.04,
        "y": 0.93
      },
      "kind": "source-note",
      "text": "GemCis treatment: gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2 on Days 1 and 8 Q3W administered for up to 8 cycles. BTC, biliary tract cancer; ECC, extrahepatic cholangiocarcinoma; ECOG, Eastern Cooperative Oncology Group; GBC, gallbladder cancer; GemCis, gemcitabine and cisplatin; ICC, intrahepatic cholangiocarcinoma; PD, progressive disease; PD-L1, programmed cell death ligand-1; PS, performance status; QnW, every n weeks; R, randomization.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ce47e37a-b13e-4a6f-89cc-bc156251f671",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.35,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "TOPAZ-1 trial design",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0dcc2182-9649-4614-9f41-86136b0f0488",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.5,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "A double-blind, multicentre, global, Phase III trial",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7f980524-4331-4ee7-81ad-96174094b739",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "clinical-trial-design",
      "slug": null,
      "matchId": "fe8e6ade-a9bc-488b-a87a-7a4da7281941",
      "evidence": "Standardized flow diagram for clinical trial methodology",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 25,
      "from": 9,
      "beatId": "5bf1753c-e4a0-4e18-b568-73af9c0043f2",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The deck presents data and results for Imfinzi TOPAZ-1 and HIMALAYA, demonstrating their effectiveness",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}